Basic Control of Reperfusion Effectively Protects Against Reperfusion Injury in a Realistic Rodent Model of Acute Limb Ischemia

Florian Dick, MD*; Jianhui Li, MD*; Marie-Noëlle Giraud, PhD; Christoph Kalka, MD; Juerg Schmidli, MD; Hendrik Tevaearai, MD, eMBA

Background—Reperfusion injury is insufficiently addressed in current clinical management of acute limb ischemia. Controlled reperfusion carries an enormous clinical potential and was tested in a new reality-driven rodent model.

Methods and Results—Acute hind-limb ischemia was induced in Wistar rats and maintained for 4 hours. Unlike previous tourniquets models, femoral vessels were surgically prepared to facilitate controlled reperfusion and to prevent venous stasis. Rats were randomized into an experimental group (n=7), in which limbs were selectively perfused with a cooled isotone heparin solution at a limited flow rate before blood flow was restored, and a conventional group (n=7; uncontrolled blood reperfusion). Rats were killed 4 hours after blood reperfusion. Nonischemic limbs served as controls. Ischemia/reperfusion injury was significant in both groups; total wet-to-dry ratio was 159±44% of normal (P=0.016), whereas muscle viability and contraction force were reduced to 65±13% (P=0.016) and 45±34% (P=0.045), respectively. Controlled reperfusion, however, attenuated reperfusion injury significantly. Tissue edema was less pronounced (132±16% versus 185±42%; P=0.011) and muscle viability (74±11% versus 57±9%; P=0.004) and contraction force (68±40% versus 26±7%; P=0.045) were better preserved than after uncontrolled reperfusion. Moreover, subsequent blood circulation as assessed by laser Doppler recovered completely after controlled reperfusion but stayed durably impaired after uncontrolled reperfusion (P=0.027).

Conclusions—Reperfusion injury was significantly alleviated by basic modifications of the initial reperfusion period in a new in vivo model of acute limb ischemia. With this model, systematic optimizations of according protocols may eventually translate into improved clinical management of acute limb ischemia. (Circulation. 2008;118:1920-1928.)

Key Words: inflammation ■ ischemia ■ peripheral vascular disease ■ prevention ■ reperfusion

A

acute limb ischemia, one of the most common peripheral vascular emergencies, is associated with extensive morbidity, mortality, and costs.1-3 Overall prognosis has not markedly improved over the decades despite major advances in surgical and pharmacological revascularization options;4,5 all-cause mortality is still in excess of 25%, and survivors face a 20% risk of major amputation.3-7

Clinical Perspective p 1928

Traditionally, clinical management has aimed at early tissue reperfusion without dedicated attention to imminent reperfusion-related injury.3,7,8 The immediate and full restoration of blood flow, however, may paradoxically aggravate previous ischemic damage by setting into motion a host of inflammatory responses that promote local tissue destruction and no reflow within the microcirculation,9-12 whereas systemic washout of toxic metabolites may lead to life-threatening systemic complications, including renal, cardiac, and pulmonary failure.11,13 Identified pathomechanisms include formation of reactive oxygen species, activation of complement system, increased leukocyte-endothelium cell adhesion, increased platelet-leukocyte aggregation, interstitial fluid accumulation, diffuse microthrombosis, and decreased endothelium-dependent vasorelaxation.

Decompressive fasciotomy currently represents the only generally accepted surgical salvage strategy after restitution of blood flow;3,7 its therapeutic potential, however, is directed to secondary complications associated with established com-
partment syndrome rather than to reperfusion injury per se. Ischemic preconditioning was found to effectively induce “ischemia and reperfusion tolerance” in a number of studies; however, it is not applicable in clinical situations in which ongoing ischemia precludes preconditioning. A different strategy is thus needed to improve the outcome of acute limb ischemia.

Controlled reperfusion protocols aim to interfere with the course of reperfusion injury at various levels. Limitation of initial blood flow and perfusion pressure, modifications of the reperfusate composition, and hypothermia all have been proposed for many years. For instance, hypothermia and low initial flow rates have been shown to decrease the severity of reperfusion injury in skeletal muscle, and flow-controlled reperfusion improved sinusoidal microcirculation in rat livers. Filtration of leukocytes reduced reperfusion-related complications in lung and myocardium, and use of a substrate-enriched reperfusate led to immediate recovery of contractile muscle function after prolonged warm ischemia. Numerous additional modifications have been proposed, including the administration of free radical scavengers, anticoagulants, and dedicated antiinflammatory and vasodilative agents, as well as the disposal of sequestered blood. However, translation of such strategies to clinical management of acute limb ischemia has remained astonishingly sparse considering the considerable clinical potential that has been reported in preliminary case series. Therefore, further applied research toward defining an optimized reperfusion protocol is clearly needed but has been hindered so far by the lack of a suitable experimental model.

We developed a reality-driven rodent model of acute limb ischemia that allows selective limb perfusion and assessment of regional and systemic in vivo events. The aim was to test a basic reperfusion protocol against immediate restoration of blood flow after warm limb ischemia of critical duration (4 hours). The protocol included flow-controlled application of an oxygen-free, acellular, and cooled heparin solution in combination with venous washout of sequestered blood, all of which could theoretically be easily applied in clinical practice. The results provide an important benchmark for more sophisticated protocols and may inspire further translational and clinical research.

Methods

Animal care and all experimental procedures were approved by the Swiss animal welfare authorities and carried out in accordance with the Principles of Laboratory Animal Care (National Institutes of Health publication 86–23, 1985) and the position statement of the American Heart Association. Wistar rats of either sex (305 ± 75 g body weight) were fed a standard diet ad libitum and transferred 1 hour before the experiment to the laboratory, where they were randomized into one of the study groups. The rats were anesthetized by continuous inhalation of isoflurane (2.5%). Facilities were temperature controlled (23°C to 25°C), and rats were restrained on heating pads in a standardized fashion to maintain their body temperature at 37°C. Animals were hydrated during experiments by intraperitoneal injection of 0.5 mL normal saline every 2 hours.

Ischemia Model

All animals were subjected to 4 hours of acute limb ischemia using an established tourniquet model of limb ischemia that was modified as follows (Figure 1): Instead of placing the tourniquet just around the limb, we first exposed the femoral vessels over an oblique groin incision and prepared the superficial epigastric artery. The common femoral artery was temporarily ligated proximally (No. 6.0 Prolene); it is important to note that the femoral vein stayed open. The tourniquet (No. 2 Prolene loop suture) was then passed underneath the femoral vessels to spare them and placed around the thigh.
as proximal as possible. Tension of the tourniquet was controlled by
the amount of weight put on the loop suture. Dose-response testing
had shown a reliable relationship between tourniquet pull and limb
perfusion (n=5; Figure 2), and a weight of 450 g was chosen for all
animals. Ischemia time began after temporary ligation of the super-
ificial epigastric artery. All rats were given an intraperitoneal bolus of
heparin (50 IU/kg body weight) after 3.5 hours of ischemia.

Reperfusion Groups
In the experimental group (n=7), a controlled reperfusion protocol
was applied to ischemic limbs before blood circulation was rein-
ستated (Figure 3). The prepared epigastric artery was used as a
conduit for vascular access to spare the femoral artery any direct
trauma. A polyethylene microcatheter (PE-10; inner diameter, 0.28 mm;
outer diameter, 0.64 mm, thinned out by heat stretching; length, 20 cm)
was inserted into the conduit and connected to a
micropump (Single Syringe Pump, Harvard Apparatus, Holliston,
Mass). The protocol included flow-controlled perfusion (0.3
mL/min) of the limb with a cooled heparin-containing crystalloid
solution (15°C, ad 1000 IU heparin and Ringer’s lactate 1000 mL)
for 20 minutes while the femoral vein was clamped and sequestered
blood was washed out with the perfusion solution through a venous
incision. The vein was repaired before blood flow was reinstated by
release of tourniquet and arterial ligatures. In the control group
(n=7), blood reperfusion was reinstated directly after ischemia
(Figure 3).

Animals were kept under continuous anesthesia for standardized
observation after blood reperfusion (4 hours) and were killed without
recovering. Tissue samples were harvested from below the knee to
exclude a possible influence of the tourniquet along the thigh. In both
groups, contralateral nonischemic limbs were used as intraindividual
controls.

Study End Points
Limb Perfusion
Perfusion was assessed simultaneously in both limbs for each
measurement with a laser Doppler imager (Moor LDI-VR, Moor
Instruments Inc, Wilmington, Del) as described previously. The
laser beam (780 nm) is reflected from moving red blood cells and
processed by dedicated software (Laser Doppler Perfusion Measure,
V51, Moor Instruments Inc). Baseline images were obtained 30
minutes after anesthesia. After application of the tourniquets, a
second image confirmed limb ischemia (Figure 4). After release of
the tourniquet, additional images were obtained immediately; after 5,
10, 15, 30, 45, and 60 minutes; and after every half hour up to 4
hours. Perfusion was measured in perfusion units and expressed as
percent of the contralateral nonischemic limb.

Tissue Edema
Edema was quantified in lateral gastrocnemius muscles by measure-
ment of the ratio of wet to dry tissue weight. Tissue samples were
blotted and weighed immediately after harvest (wet weight) and
placed in a drying oven (55°C) until a constant weight was obtained
(dry weight; mean, 48 hours). Edema was indicated by an increase in
the ratio of wet to dry tissue weight and expressed as percent of the
paired control limb.
Tissue Viability
Tissue viability was estimated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described in detail before. Tetrizolium salt (MTT; Sigma, St Louis, Mo) is reduced to water-insoluble colored formazan crystals by mitochondrial activity. Samples of medial gastrocnemius muscles were incubated with 3 mL PBS (pH 7.4) and 0.3 mg MTT. After incubation, formazan crystals were extracted from samples, and their optical density was determined at 570 nm with a microplate reader (Infinite 200 spectrophotometer, Tecan, Männedorf, Switzerland). Viability index (arbitrary units) is expressed as an optical density at 570 nm after adjustment for dry tissue weight. In each analysis, a sample of dead tissue (obtained from rat muscle harvested ≥36 hours earlier and stored at room temperature) was included for background noise determination.

Muscle Contractile Properties
Excitability and contractility were tested on soleus muscles as described. Harvested muscles were bathed in oxygenated Tyrode’s solution (NaCl 118 mmol/L, KCl 4.7 mmol/L, MgSO4 1.2 mmol/L, NaHCO3 24 mmol/L, KH2PO4 1.1 mmol/L, and glucose 4.5 mmol/L at pH 7.4 and 25°C) with increasing CaCl2 concentrations up to 1.25 mmol/L. Association of maximal muscle twitch and muscle tension (preload) was assessed in a force transducer (muscle tester ORG, Heidelberg, Germany) by standardized stimulation (5 V for 0.5 ms at 2 Hz). Force and speed of contractions were recorded at optimal preload. Cross-sectional area of muscles was calculated assuming the geometry of a cylinder with a specific gravity of 1.06 g/cm³. Twitch amplitude and derivatives were corrected for cross-sectional area and were expressed as percent of paired control limbs.

Statistical Methods
Investigators were blinded to study group for data analysis. Conventional descriptive statistics were used, giving mean±SD, medians (interquartile range), or percent of paired controls. Distributions were assumed to be nonparametric and compared by appropriate tests throughout. Paired tests were used for comparisons between ischemic and control limbs, and unpaired tests were used for comparisons between study groups. Proportions were compared by use of Fisher’s exact test, and the difference in the kinetic of the 2 reperfusion curves (Figure 5) was assessed by repeated-measures Greenhouse Geisser ANOVA. All tests were 2 tailed. Statistical significance was accepted for values of P≤0.05 and was alternatively adjusted according to Bonferroni (0.017) to appraise results under the assumption of multiple hypothesis testing. All analyses were performed with SPSS for Windows, version 15.0 (SPSS Inc, Chicago, Ill).

Results
All experiments were performed within 1 month after the methodology was established. All animals survived the experiments and were killed according to protocol. Induction of ischemia was surgically feasible in the described manner. Patency of the main venous outflow was ascertained by direct observation of moving blood in femoral veins through the operating microscope. Cannulation of the superficial epigastric artery was possible in all animals and added a mean of 10 minutes of operating time to the ischemic period of the experimental group. Preliminary experiments had demonstrated efficacious arterial access by use of methylene blue and by observation of watery immersion from iatrogenic toe lesions during reperfusion. During the study, flow-controlled reperfusion circulated undisturbed and turned venous wash-out expeditiously watery and limbs anemic in all animals, whereas no leaks were observed at cannulation sites. The reperfusion protocol added 20 minutes to the experimental group, which eventually underwent 4.5 hours of ischemia as opposed to 4 hours in the control group (Figure 3).

Return of circulation followed a different dynamic in the 2 study groups after release of the tourniquet (Figures 4 and 5). Limb perfusion returned more promptly at first in the control group but stayed durably impaired, whereas circulation returned less rapidly in the experimental group but normalized completely over time. The total difference in the dynamic of the 2 reperfusion curves over time became statistically significant beginning at 180 minutes in repeated-measures ANOVA. Hence, recovery of limb circulation was significantly better after controlled reperfusion than after immediate restoration of blood flow over the first 4 hours (P=0.027 by Greenhouse Geisser).

Main findings regarding severity of ischemia-reperfusion injury are given in the Table. The modified tourniquet model induced reliably significant ischemia/reperfusion injury in both study groups. Ischemic limbs across the groups present-
ed a total mean edema index of 159 ± 44% (P = 0.016), a mean residual muscle viability of 65 ± 13% (P = 0.016), and a mean residual contraction force of 45 ± 34% (P = 0.045) compared with their nonischemic controls (100%) by paired testing. Paired differences also were statistically significant within individual groups except for contractility, which was not significantly impaired after controlled reperfusion (the Table).

However, the type of reperfusion was clearly associated with the severity of ischemia/reperfusion injury. Whereas findings in nonischemic control limbs were very similar in both groups (P > 0.5), supporting the assumption of compa-

<table>
<thead>
<tr>
<th>Table. Characteristics of the Study Groups and Main Results of the Experiment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Statistic</strong></td>
</tr>
<tr>
<td>Median weight, g</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
</tr>
<tr>
<td>Edema</td>
</tr>
<tr>
<td>Ischemic limbs</td>
</tr>
<tr>
<td>Control limbs</td>
</tr>
<tr>
<td>Edema index, %</td>
</tr>
<tr>
<td>Muscle viability</td>
</tr>
<tr>
<td>Ischemic limbs</td>
</tr>
<tr>
<td>Control limbs</td>
</tr>
<tr>
<td>Muscle viability index, %</td>
</tr>
<tr>
<td>Contractility force index, %</td>
</tr>
</tbody>
</table>

Values are given as median (interquartile range) when appropriate. Edema (ratio of wet to dry tissue weight), muscle viability (MTT assay), and contractility are calculated as indexes (percent of normal).

*Nonparametric 2-sided unpaired test (Mann–Whitney U).
†Two-sided Fisher’s exact test.
‡Nonparametric 2-sided paired test (Wilcoxon).
§Multivariate ANOVA testing of intraindividual differences stratified for ischemia.
rability, severity of reperfusion injury was significantly less pronounced in the experimental group than in the control group. Differences were statistically significant in direct comparisons of the raw results and stayed so after adjustment for individual variation by calculation of index values relative to control limbs (the Table). The controlled reperfusion protocol attenuated edema formation significantly (137% versus 191% in the control group; \( P < 0.011 \); Figure 6). Similarly, it preserved muscle viability (70% versus 61%; \( P < 0.004 \); Figure 7) and muscle contractility (59% versus 23%; \( P < 0.045 \); Figure 6) much better than early uncontrolled blood reperfusion. The adjustment for background noise of the MTT assay, however, confirmed residual mitochondrial activity in both study groups (Figure 7).

**Discussion**

The present study aimed to explore the concept of controlled reperfusion in a new reality-driven rodent model of acute limb ischemia to support the transfer of this promising therapeutic concept to a more systematic clinical application. It emerged that the proposed model is suitable for representative in vivo studies and provides a missing link for structured translational research. Interestingly, very basic management of physical and chemical conditions of the initial reperfusion phase already conveyed effective protection against reperfusion-related injury.

Controlled reperfusion is increasingly being recognized as an effective approach to ongoing ischemia in various organs.\(^{15}\) Originally described in ischemic myocardium,\(^ {32}\) it soon became established in transplantation and cardiac surgery.\(^ {15}\) For acute limb ischemia, however, clinical data are scarce. Although small case series have reported striking results after up to 24 hours of ischemia\(^ {24,25,33}\) and a recent study claimed impressive benefits over simple embolectomy and immediate blood reperfusion,\(^ {27}\) a randomized controlled trial could not show any benefits regarding local outcome.\(^ {26}\) Nevertheless, experimental data are very promising,\(^ {15}\) and clinical success may depend mainly on a systematic optimization of an applicable reperfusion protocol worth being translated.\(^ {34}\) Essentially, our experiment reconfirmed the enormous clinical potential of controlled reperfusion and showed that simple and clinically available measures may already offer impressive protection against reperfusion injury (the Table). Moreover, the generic character of these modifications rendered this protocol a suitable benchmark for systematic preclinical refinements.

Reinstatement of blood perfusion is the obvious therapeutic goal in ischemia. However, perfusion is of use only if flow is actually brought to the suffocated cells. After acute ischemia, a no-reflow phenomenon may emerge as the consequence of a multifactorial vicious circle.\(^ {12}\) For example, immediate and full restoration of blood flow (shock reperfusion) has been shown to cause microvascular shutdown and congestion,\(^ {12,20}\) whereas increased hydrostatic forces enhance arteriovenous shunting and edema formation.\(^ {17}\) Conversely, flow control during initial reperfusion was effective in improving the microvascular stream\(^ {20}\) and consequently reduced peripheral vascular resistance and edema formation.\(^ {19,35}\) Other important factors promoting no reflow include inflammatory destruction of vascular beds and microthrombosis.

![Figure 6. Comparison of edema (left) and contraction force (right) indexes of ischemic limbs after the controlled reperfusion protocol \( (n=7; \text{open boxes}) \) and uncontrolled reperfusion \( (n=7; \text{gray boxes}) \). Findings are expressed as percent of normal (horizontal interrupted bars).](image-url)
Edema is directly associated with the compartment syndrome, the ultimate local complication of ischemia/reperfusion injury, and is therefore an independent therapy target. Like no reflow, its genesis is multifactorial. Besides hydrostatic shifts during shock reperfusion, ischemic endothelium is prone to leaking osmotic macromolecules, which is further promoted by ongoing inflammation. Indeed, eliminating the key initiators of inflammation from the initial reperfusion period such as oxygen, complement factors, and leukocytes has been found to be highly effective in alleviating local injury and tissue edema. In our present study, we combined these basic mechanisms with the known cytoprotective effects of hypothermia and supplemented heparin to interfere with propagation of microthrombosis and local inflammation. Despite a prolonged net ischemic time, this protocol impressively improved local outcome compared with shock reperfusion (Figure 2).

Edema is directly associated with the compartment syndrome, the ultimate local complication of ischemia/reperfusion injury, and is therefore an independent therapy target. Like no reflow, its genesis is multifactorial. Besides hydrostatic shifts during shock reperfusion, ischemic endothelium is prone to leaking osmotic macromolecules, which is further promoted by ongoing inflammation. Indeed, eliminating the key initiators of inflammation from the initial reperfusion period such as oxygen, complement factors, and leukocytes has been found to be highly effective in alleviating local injury and tissue edema. In our present study, we combined these basic mechanisms with the known cytoprotective effects of hypothermia and supplemented heparin to interfere with propagation of microthrombosis and local inflammation. Despite a prolonged net ischemic time, this protocol impressively improved local outcome compared with shock reperfusion (Figure 2).

Unlike the control group, limb perfusion recovered completely in the experimental group. Interestingly, the kinetic of perfusion recovery also was significantly different ($P=0.027$; Figure 5) and resembled very closely the spontaneous reperfusion curve observed in a previous study after subclinical ischemia (1 hour). Tissue edema was enormously reduced and tissue viability was highly increased, which certainly contributed to the marked preservation of contractility (the Table). These effects were more pronounced in earlier reports; however, selective in vivo reperfusion has not been used in rodents before. Therefore, comparability was limited because these data stemmed from isolated rat hind limbs or larger animal models with incomplete ischemia. Moreover, these reports used dedicated solutions to prevent edema or to preserve cell viability by adapted supply of substrates. With a generic protocol like ours used as a benchmark, however, such optimizations can eventually be systematized. Indeed, the modular character of our experimental protocol allows a structured and systematic evaluation of individually modulated perfusion parameters or an ever-growing spectrum of potentially effective pharmacological adjuncts.

The explicit aim of the model design was to amend translational research. Earlier rodent models have used tourniquets or rubber bands and lacked vascular access for selective reperfusion. Venous stasis as a consequence of these approaches, however, is not a part of clinical limb ischemia and has been associated with severe damage to the microcirculation in earlier studies. In our model, patency of the femoral vein was confirmed by direct observation, and the reperfusion dynamic in the control group strongly suggested that microcirculation had been relatively protected. In addition, blood circulation recovered remarkably better in our model after 4 hours of ischemia (80%; Figure 5) than in a recently reported 3-hour ischemia model involving venous occlusion (50%). Together with a reliable vascular access, our model overcame a major limitation of earlier rodent models.

Reflection of clinically relevant outcome is crucial for an experimental model to qualify as translational platform. Our
model consistently produced significant clinical signs of ischemia/reperfusion injury in all tested limbs compared with nonischemic controls (the Table), and the extent of injury was found to be in the same range as reported before for similar settings.\textsuperscript{28,35,38,42} The timing of experiments is another important aspect because reperfusion models should reflect clinically relevant degrees of ischemia; however, any therapeutic benefit is being lost as soon as irreversible tissue damage occurs. Clinically, the critical threshold for acutely ischemic limbs is usually estimated to be \( \approx 6 \) hours.\textsuperscript{9} However, analogy with tourniquet ischemia is limited because clinical ischemia is normally not complete. Indeed, the critical acute ischemia window for traumatic amputations or ischemic surgical flaps is usually much shorter, ranging between 2 and 4 hours.\textsuperscript{9,11} Hence, most models of complete peripheral ischemia settle for intervals between 2 and 4 hours, depending on the research question.\textsuperscript{28,35,38} In our experimental setting, we chose an interval (4 hours) that ranged at the upper end of this critical window because we aimed to maximize reperfusion-related injury to facilitate the evaluation of reperfusion protocols in a clinically relevant setting.

The duration of the observation period after reperfusion is of similar relevance. Pathological investigations have shown that reperfusion-related changes occurred essentially within the first hour and that myonecrosis did not increase after that.\textsuperscript{9} Another study investigated 3 hours of complete ischemia and reported that local injury was very similar after 4 and 48 hours of reperfusion.\textsuperscript{38} In contrast, others found complete recovery of humoral markers of cell damage within 24 hours (2 hours of ischemia). Local injury, however, persisted in this study and was demonstrated by tissue assays.\textsuperscript{42} In our study, we first aimed to standardize the experimental conditions to validate our approach and thus decided to keep the animals under continuous anesthesia. On the basis of the arguments above, we accepted a 4-hour observation period as sufficiently representative to assess local outcome.\textsuperscript{28,35} Nevertheless, future experiments will obviously have to account for longer follow-up periods, particularly in the assessment of systemic outcome.

**Study Limitations**

Some methodological limitations must be considered in the interpretation of the data of this series. First, because of organizational concerns in our unit, Wistar rats of different sexes and weights were used throughout the experiment. However, similar distributions of sex and weight were ascertained by randomization (the Table) and seem not to have influenced results, which were astonishingly consistent. Our study also may be criticized for the small number of animals. Given the primary goal of establishing and validating a new reality-driven rodent model, this study was conceived to suit this purpose, venous evacuation of sequestered blood was included in the baseline protocol because it has been associated with improved survival in human studies.\textsuperscript{26}

**Conclusions**

The present study proposed and validated an improved reality-driven rodent model of acute limb ischemia that, unlike earlier models, affords emulation of clinical management by controlled reperfusion. A basic set of modifications of the initial reperfusion phase, which could theoretically be applied easily in clinical practice, appeared highly protective and highlighted the clinical potential of controlled reperfusion. Moreover, it provided a methodological framework for structured translational research in this field. It remains to be seen how much additional local and systemic benefit can be achieved by pharmacological optimization of the reperfusate solution.

**Acknowledgments**

We thank our biostatistician, Brigitta Gahl, MSc, for invaluable help with the analyses and Nicolas Diehm, MD, for dedicated input during the setup of the animal model.

**Sources of Funding**

Dr Dick received independent stipendiary support for a vascular research fellowship from the Swiss National Funds (PBBSB-120858) and the Lichtenstein Stiftung, Basel, Switzerland, during part of his time.

**Disclosures**

None.

**References**

Clinical Management of Acute Limb Ischemia

Clinical management of acute limb ischemia has not progressed fundamentally since safe and fast restoration of blood flow became possible with the introduction of balloon catheters. Although the restored circulation is absolutely vital, it may paradoxically also lead to exacerbated local injury and systemic complications, which essentially account for the poor prognosis. Controlled reperfusion with specific modifications of the initial reperfusion period, as routinely applied in transplantation or cardiac operations, is thought to have great potential to improve clinical outcome. However, the lack of a suitable translational model of limb ischemia has hindered the systematic development of an optimal reperfusion protocol for acute limb ischemia. The relative importance of physical and biochemical (perfusion pressure, flow rate, temperature, oxygen content, osmolarity), biological (filtration of leukocytes or inflammatory molecules), or pharmacological (free radical scavengers, anticoagulant and antiinflammatory agents, Na⁺/H⁺ pump inhibitors) modifications still needs to be investigated. Our study validated a new reality-driven rodent model of controlled limb reperfusion that is suited for both structured translational research and molecular investigations because it allows in vivo studies of regional and systemic events during ischemia/reperfusion injury. Interestingly, a basic and, in clinical practice, theoretically easily applicable reperfusion protocol already conveyed major protective effects against reperfusion injury by flow-controlled application of a cooled isotonc hepatorxin solution. These findings highlight the enormous clinical potential of controlled reperfusion and, as a benchmark for refinements, provide the methodological framework for systematic research into an optimized and clinically applicable reperfusion protocol that may eventually translate into improved patient care.
Basic Control of Reperfusion Effectively Protects Against Reperfusion Injury in a Realistic Rodent Model of Acute Limb Ischemia

Florian Dick, Jianhui Li, Marie-Noëlle Giraud, Christoph Kalka, Juerg Schmidli and Hendrik Tevaearai

_Circulation_. 2008;118:1920-1928; originally published online October 20, 2008; doi: 10.1161/CIRCULATIONAHA.108.787754

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/118/19/1920

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2008/11/06/CIRCULATIONAHA.108.787754.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/